Dark

Check out our API

FREQ
Frequency Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Nov 3, 2023

14.98USD+5.941%(+0.84)6,183

Pre-market

0.00USD-100.000%(-14.14)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 4, 2022

07:30AM EST Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 10, 2021

04:15PM EST Frequency Therapeutics Says On Dec. 10 Co Entered Into Equity Distribution Agreement With Oppenheimer To Sell Up To $125M In Stock Benzinga

Dec 9, 2021

09:46PM EST Frequency Therapeutics Shares Results From FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements In Noise Benzinga

08:15AM EST Frequency Therapeutics, Inc. (FREQ) reported the results from its FX-322-113 study, a placebo-controlled trial evaluating the administration of FX-322 in subjects with severe sensorineural hearing loss. In the study, FX-322 was associated with a hearing signal as shown by improvements by four subjects in a sentence-in-noise test. RTTNews

07:38AM EST Frequency Therapeutics : FX-322 Associated With Hearing Signal RTTNews

07:30AM EST Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise Business Wire

Nov 15, 2021

10:58AM EST Frequency Therapeutics Q3 EPS $(0.73) Down From $(0.16) YoY Benzinga

07:30AM EST Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results Business Wire

Nov 9, 2021

12:16PM EST Frequency Therapeutics Earlier Gave Unaudited Cash, Cash Equivalents, Marketable Securities $160.5M As Of Sept. 30, 2021 Benzinga

07:30AM EST Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis Business Wire

Oct 27, 2021

08:05AM EDT Frequency Therapeutics Virtual R&D Event To Detail FX-322 Clinical Advances, A New Program For Hearing Restoration And In Vivo Data From MS Remyelination Program Nov. 9 Benzinga

07:30AM EDT Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program Business Wire

Oct 21, 2021

12:11PM EDT Frequency Therapeutics Announces First Subject Dosed In FX-322 Phase 2b Acquired Sensorineural Hearing Loss Study And FDA Agreement On Speech Perception As Primary Endpoint Benzinga

07:36AM EDT Frequency Therapeutics Says First Subject Dosed In FX-322 Phase 2b Acquired Sensorineural Hearing Loss Study RTTNews

07:30AM EDT Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint Business Wire

Oct 20, 2021

07:59AM EDT Clinicaltrials.gov Site Shows Frequency Therapeutics Study FX-322 in Adults With Acquired Sensorineural Hearing Loss Recruiting Benzinga

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

Sep 23, 2021

07:57AM EDT The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data Benzinga

Sep 22, 2021

10:05AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021 Benzinga

08:02AM EDT FREQ : New Results Suggest Hearing Of Individuals RTTNews

07:38AM EDT FREQ : Results Suggest Hearing Of Individuals Administered With Single Dose Of FX-322 May Improve Over Extended Periods RTTNews

07:33AM EDT Frequency Therapeutics Says In Follow-Up To Phase 1b Learning Study Of FX-322 Results, 'Some Subjects with Sensorineural Hearing Loss Show Increased Speech Perception Up to Twelve Months After Dosing' Benzinga

07:30AM EDT Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points Business Wire

06:17AM EDT Goldman Sachs Downgrades Frequency Therapeutics to Neutral, Lowers Price Target to $9 Benzinga

Sep 17, 2021

07:36AM EDT The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold Benzinga

Sep 8, 2021

07:30AM EDT Frequency Therapeutics to Present at Upcoming Investor Conferences Business Wire

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 12, 2021

07:38AM EDT Frequency Therapeutics Q2 Net Loss $17.7 Mln Vs. $6.0 Mln Prior Year RTTNews

07:30AM EDT Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results Business Wire

Jul 30, 2021

08:49PM EDT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Frequency Therapeutics, Inc. and Encourages Investors to Contact the Firm Business Wire

Jul 26, 2021

03:24PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jul 21, 2021

07:07AM EDT Securities Fraud Class Action Lawsuit Against Frequency Therapeutics - Contact Johnson Fistel PR Newswire

Jul 15, 2021

06:09PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jul 8, 2021

10:02AM EDT FREQ, ACRX & RLX Shareholder Alert: Bronstein, Gewirtz & Grossman GlobeNewswire Inc

Jul 7, 2021

08:52PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Jun 23, 2021

02:10PM EDT Pomerantz Law Firm Announces the Filing of a Class Action Against Frequency PR Newswire

Jun 4, 2021

10:34AM EDT Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Frequency, Inc. (Frequency or WPG) (NASDAQ: FREQ) in the United States District Court for the District of Massachusetts on behalf of those who purchased or otherwise acquired Frequency publicly traded securities between November 16, 2020, and March 22, 2021, inclusive (the Class Period). GlobeNewswire Inc

May 25, 2021

07:30AM EDT Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences Business Wire

May 20, 2021

08:30AM EDT Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America's Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss Business Wire

May 13, 2021

07:35AM EDT Frequency Therapeutics Q1 EPS $(0.60) Down From $(0.16) YoY, Sales $4.65M Down From $7.26M YoY Benzinga

07:34AM EDT Frequency Therapeutics Q1 Loss Per Share $0.60 Vs Loss $0.16 Last Year RTTNews

07:30AM EDT Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results Business Wire

Apr 13, 2021

07:12AM EDT Frequency Therapeutics Expands Clinical Development Team With The Addition Of Jeffery Lichtenhan RTTNews

07:00AM EDT Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science Business Wire

Apr 9, 2021

07:08AM EDT Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference Apr. 14 Benzinga

07:00AM EDT Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference Business Wire

Mar 31, 2021

07:41AM EDT The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO Benzinga

Mar 29, 2021

04:02PM EDT Frequency Therapeutics Q4 EPS $(0.30) vs $(0.19) In Same Qtr. Last Year Benzinga

04:02PM EDT Frequency Therapeutics Q4 Sales $10M vs $4.7M In Same Qtr. Last Year, Net Loss $10.2M vs $5.5M Year Over Year; Co. Had $220.3M In Cash, Cash Equivalents, Short-Term Investments As Of Dec. 31, 2020 Benzinga

04:01PM EDT Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire

Mar 27, 2021

01:01PM EDT The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week Benzinga

Mar 24, 2021

08:59AM EDT The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping Benzinga

08:40AM EDT 10 Biggest Price Target Changes For Wednesday Benzinga

07:01AM EDT Oppenheimer Maintains Outperform on Frequency Therapeutics, Lowers Price Target to $20 Benzinga

Mar 23, 2021

02:41PM EDT Mid-Afternoon Market Update: Dow Falls Over 100 Points; Pacific Mercantile Bancorp Shares Surge Benzinga

12:05PM EDT Mid-Day Market Update: Crude Oil Down 4.5%; Hoth Therapeutics Shares Spike Higher Benzinga

10:19AM EDT Mid-Morning Market Update: Markets Edge Higher; IHS Markit Profit Beats Views Benzinga

07:54AM EDT Frequency Therapeutics Stock Craters After FX-322's Four Weekly Regime Shows No Benefit In Sensorineural Hearing Loss Benzinga

07:45AM EDT Frequency Therapeutics Earlier Announced Interim FX-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit Benzinga

07:00AM EDT Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen Business Wire

Feb 23, 2021

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

07:12AM EST Frequency Therapeutics' FX-322 Data Published In Peer-Reviewed Journal Benzinga

Feb 22, 2021

04:01PM EST Frequency Therapeutics Highlights Publication Of Phase 1/2 Data For Hearing Improvements Related To FX-322 Benzinga

04:00PM EST Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322 Business Wire

Feb 9, 2021

08:10AM EST The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement Benzinga

Feb 8, 2021

07:12AM EST Frequency Therapeutics Appoints Kevin Franck As SVP, Strategic Marketing And New Product Planning RTTNews

07:00AM EST Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning Business Wire

Feb 4, 2021

07:22AM EST The Daily Biotech Pulse: Novartis COVID-19 Drug Readout, Merck And Roche Earnings, 3 IPOs Benzinga

Feb 3, 2021

07:31AM EST The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision Benzinga

Feb 2, 2021

08:05AM EST The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment Benzinga

Jan 28, 2021

08:03AM EST The Daily Biotech Pulse: Decision Day For Amgen, Zymeworks Sinks On Data, Ortho Clinical Diagnostics IPO Benzinga

Jan 27, 2021

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2021 Benzinga

05:59AM EST JP Morgan Upgrades Frequency Therapeutics to Overweight, Announces $56 Price Target Benzinga

Jan 19, 2021

07:31AM EST Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer Business Wire

Jan 5, 2021

07:30AM EST Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 18, 2020

08:00AM EST Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss Business Wire

07:48AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Vote, Mesoblast Sinks On Data Benzinga

07:45AM EST The Daily Biotech Pulse: FDA Nod For Amgen's Biosimilar, Moderna's Vaccine Approved, Mesoblast Sinks On Data Benzinga

Dec 17, 2020

08:10AM EST The Daily Biotech Pulse: MacroGenics Breast Cancer Drug Wins FDA Approval, Adcom Test Awaits Moderna, Virios To Make Wall Street Debut Benzinga

Dec 16, 2020

07:15AM EST The Daily Biotech Pulse: Novartis Gets Adcom Backing, Sio Gene Data, 2 IPOs, BioNTech Clinches China Vaccine Supply Deal Benzinga

Dec 15, 2020

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 11, 2020

08:11AM EST The Daily Biotech Pulse: Pfizer-BioNTech Receive FDA Panel Backing, Sanofi-GSK Disclose Delay In Vaccine Program, 4 Biotechs To Debut On Wall Street Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

Dec 1, 2020

07:35AM EST Frequency Therapeutics Appoints Peter Pfreundschuh As Chief Financial Office Benzinga

07:34AM EST Frequency Therapeutics Appoints Peter Pfreundschuh As CFO RTTNews

07:30AM EST Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer Business Wire

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 20, 2020

07:54AM EST Cramer Gives His Opinion On Workhorse, Rackspace Technology, More Benzinga

Nov 19, 2020

06:54PM EST Jim Cramer On CNBC: Frequency Therapeutics Is Speculative But I Have No Problem With It Benzinga

Nov 16, 2020

08:24AM EST Frequency Therapeutics Inc Files For Mixed Shelf Of Up To $300M Benzinga

07:50AM EST Frequency Therapeutics Q3 Revenue $11.2 Mln, Net Loss $5.3 Mln RTTNews

07:32AM EST Frequency Therapeutics Q3 EPS $(0.16) Up From $(0.73) YoY, Sales $11.25M Down From $24.24M YoY Benzinga

07:30AM EST Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results Business Wire

Oct 29, 2020

07:05AM EDT Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis Benzinga

Sep 25, 2020

09:00AM EDT Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors Business Wire

Sep 22, 2020

07:33AM EDT Frequency Therapeutics Completes Enrollment Of FX-322 Phase 2a Study For Sensorineural Hearing Loss RTTNews

Sep 13, 2020

03:00PM EDT Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322 Business Wire

Sep 8, 2020

08:00AM EDT Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings Business Wire

Aug 12, 2020

07:40AM EDT Frequency Therapeutics Q2 Loss Per Share $0.19 Vs Loss $3.42 Last Year RTTNews

07:36AM EDT Frequency Therapeutics Says Expects To Complete Enrollment Of FX-322 Phase 2A Study For Sensorineural Hearing Loss By Early Q4 2020 Benzinga

07:36AM EDT Frequency Therapeutics Q2 EPS $(0.19), Sales $8.50M Benzinga

07:30AM EDT Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results Business Wire

Jul 25, 2020

05:18PM EDT Notable Insider Buys: Guess, FedEx And More Benzinga

Jul 17, 2020

04:08PM EDT Frequency Therapeutics Announces $42 Mln Private Placement RTTNews

04:05PM EDT Frequency Therapeutics Announces $42 Million Private Placement Business Wire

Jul 14, 2020

06:58AM EDT Oppenheimer Initiates Coverage On Frequency Therapeutics with Outperform Rating, Announces Price Target of $36 Benzinga

Jul 13, 2020

04:17PM EDT Frequency Therapeutics Shares Tick Higher After Hours; Hearing Oppenheimer Initiates Coverage With Outperform Rating, $36 Price Target Benzinga

Share